Precise	O
prediction	O
of	O
activators	B:C0751968
for	O
the	O
human	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
using	O
structure	O
-	O
based	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
methods	O
.	O

Precise	O
prediction	O
of	O
activators	O
for	O
the	O
human	B:C0086418
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
using	O
structure	O
-	O
based	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
methods	O
.	O

Precise	O
prediction	O
of	O
activators	O
for	O
the	O
human	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
using	O
structure	O
-	O
based	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
methods	O
.	O

Precise	O
prediction	O
of	O
activators	O
for	O
the	O
human	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
using	O
structure	B:C0026383
-	O
based	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
methods	O
.	O

Precise	O
prediction	O
of	O
activators	O
for	O
the	O
human	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
using	O
structure	O
-	O
based	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
methods	B:C0025663
.	O

The	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
(	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
NR1I3	O
)	I:C0663285
regulates	O
the	I:C2755857
expression	I:C2755857
of	O
numerous	O
drug-	O
metabolizing	I:C0683140
enzymes	O
and	O
transporters	O
.	O

The	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
(	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
,	O
NR1I3	O
)	I:C0663285
regulates	O
the	I:C2755857
expression	I:C2755857
of	O
numerous	O
drug-	O
metabolizing	I:C0683140
enzymes	O
and	O
transporters	O
.	O

The	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
(	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
NR1I3	B:C0663285
)	I:C0663285
regulates	O
the	I:C2755857
expression	I:C2755857
of	O
numerous	O
drug-	O
metabolizing	I:C0683140
enzymes	O
and	O
transporters	O
.	O

The	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
(	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
NR1I3	O
)	I:C0663285
regulates	B:C2755857
the	I:C2755857
expression	I:C2755857
of	O
numerous	O
drug-	O
metabolizing	I:C0683140
enzymes	O
and	O
transporters	O
.	O

The	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
(	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
NR1I3	O
)	I:C0663285
regulates	O
the	I:C2755857
expression	I:C2755857
of	O
numerous	O
drug-	B:C0683140
metabolizing	I:C0683140
enzymes	O
and	O
transporters	O
.	O

The	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
(	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
NR1I3	O
)	I:C0663285
regulates	O
the	I:C2755857
expression	I:C2755857
of	O
numerous	O
drug-	O
metabolizing	I:C0683140
enzymes	B:C0014442
and	O
transporters	O
.	O

The	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
(	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
NR1I3	O
)	I:C0663285
regulates	O
the	I:C2755857
expression	I:C2755857
of	O
numerous	O
drug-	O
metabolizing	I:C0683140
enzymes	O
and	O
transporters	B:C0007292
.	O

The	O
upregulation	B:C0041904
of	O
various	O
enzymes	O
,	O
including	O
CYP2B6	O
,	O
by	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activators	O
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
(	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
)	O
.	O

The	O
upregulation	O
of	O
various	O
enzymes	B:C0014442
,	O
including	O
CYP2B6	O
,	O
by	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activators	O
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
(	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
)	O
.	O

The	O
upregulation	O
of	O
various	O
enzymes	O
,	O
including	O
CYP2B6	B:C0534137
,	O
by	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activators	O
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
(	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
)	O
.	O

The	O
upregulation	O
of	O
various	O
enzymes	O
,	O
including	O
CYP2B6	O
,	O
by	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
activators	O
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
(	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
)	O
.	O

The	O
upregulation	O
of	O
various	O
enzymes	O
,	O
including	O
CYP2B6	O
,	O
by	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activators	B:C0751968
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
(	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
)	O
.	O

The	O
upregulation	O
of	O
various	O
enzymes	O
,	O
including	O
CYP2B6	O
,	O
by	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activators	O
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	B:C0687133
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
(	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
)	O
.	O

The	O
upregulation	O
of	O
various	O
enzymes	O
,	O
including	O
CYP2B6	O
,	O
by	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activators	O
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	O
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
(	O
drug	B:C0687133
-	I:C0687133
drug	I:C0687133
interactions	I:C0687133
)	O
.	O

To	O
date	O
,	O
however	O
,	O
few	O
effective	O
computational	B:C1516769
approaches	I:C1516769
for	O
identifying	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activators	O
exist	O
.	O

To	O
date	O
,	O
however	O
,	O
few	O
effective	O
computational	O
approaches	I:C1516769
for	O
identifying	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
activators	O
exist	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
-	O
QSAR	O
)	O
models	B:C3161035
to	O
predict	O
the	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
of	O
compounds	O
emerging	O
in	O
the	O
drug	O
-	I:C0920472
discovery	I:C0920472
process	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
-	O
QSAR	O
)	O
models	O
to	O
predict	O
the	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
of	O
compounds	O
emerging	O
in	O
the	O
drug	O
-	I:C0920472
discovery	I:C0920472
process	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
-	O
QSAR	O
)	O
models	O
to	O
predict	O
the	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	B:C1514758
potency	O
of	O
compounds	O
emerging	O
in	O
the	O
drug	O
-	I:C0920472
discovery	I:C0920472
process	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
-	O
QSAR	O
)	O
models	O
to	O
predict	O
the	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
of	O
compounds	B:C1254351
emerging	O
in	O
the	O
drug	O
-	I:C0920472
discovery	I:C0920472
process	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
-	O
QSAR	O
)	O
models	O
to	O
predict	O
the	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
of	O
compounds	O
emerging	O
in	O
the	O
drug	B:C0920472
-	I:C0920472
discovery	I:C0920472
process	O
.	O

Models	B:C3161035
were	O
constructed	O
using	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
(	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	O
binding	I:C1517880
to	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	O
-	I:C1522290
docking	I:C1522290
using	O
28	O
compounds	I:C1254351
as	O
a	O
training	O
set	O
.	O

Models	O
were	O
constructed	O
using	O
comparative	B:C1513380
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
(	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	O
binding	I:C1517880
to	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	O
-	I:C1522290
docking	I:C1522290
using	O
28	O
compounds	I:C1254351
as	O
a	O
training	O
set	O
.	O

Models	O
were	O
constructed	O
using	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
(	O
comparative	B:C1513380
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	O
binding	I:C1517880
to	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	O
-	I:C1522290
docking	I:C1522290
using	O
28	O
compounds	I:C1254351
as	O
a	O
training	O
set	O
.	O

Models	O
were	O
constructed	O
using	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
(	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	B:C1517880
binding	I:C1517880
to	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	O
-	I:C1522290
docking	I:C1522290
using	O
28	O
compounds	I:C1254351
as	O
a	O
training	O
set	O
.	O

Models	O
were	O
constructed	O
using	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
(	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	O
binding	I:C1517880
to	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	O
-	I:C1522290
docking	I:C1522290
using	O
28	O
compounds	I:C1254351
as	O
a	O
training	O
set	O
.	O

Models	O
were	O
constructed	O
using	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
(	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	O
binding	I:C1517880
to	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	B:C1522290
-	I:C1522290
docking	I:C1522290
using	O
28	O
compounds	I:C1254351
as	O
a	O
training	O
set	O
.	O

Models	O
were	O
constructed	O
using	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
(	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	O
binding	I:C1517880
to	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	O
-	I:C1522290
docking	I:C1522290
using	O
28	B:C1254351
compounds	I:C1254351
as	O
a	O
training	O
set	O
.	O

The	O
comparative	B:C1513380
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
model	O
,	O
modified	O
by	O
adding	O
a	O
lipophilic	O
parameter	O
with	O
calculated	O
logD7.4	O
(	O
S+logD7.4	O
)	O
,	O
demonstrated	O
statistically	O
good	O
predictive	O
ability	O
(	O
r(	O
2	O
)	O
=	O
0.99	O
,	O
q	O
(	O
2	O
)	O
=	O
0.74	O
)	O
.	O

The	O
comparative	O
molecular	I:C1513380
field	I:C1513380
analysis	I:C1513380
model	B:C3161035
,	O
modified	O
by	O
adding	O
a	O
lipophilic	O
parameter	O
with	O
calculated	O
logD7.4	O
(	O
S+logD7.4	O
)	O
,	O
demonstrated	O
statistically	O
good	O
predictive	O
ability	O
(	O
r(	O
2	O
)	O
=	O
0.99	O
,	O
q	O
(	O
2	O
)	O
=	O
0.74	O
)	O
.	O

We	O
also	O
confirmed	O
the	O
excellent	O
predictability	O
of	O
the	O
3D	O
-	O
QSAR	O
model	B:C3161035
for	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activation	O
(	O
r	O
(	O
2	O
)	O
pred	O
=	O
0.71	O
)	O
using	O
seven	O
compounds	O
as	O
a	O
test	O
set	O
for	O
external	O
validation	I:C1519941
.	O

We	O
also	O
confirmed	O
the	O
excellent	O
predictability	O
of	O
the	O
3D	O
-	O
QSAR	O
model	O
for	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
activation	O
(	O
r	O
(	O
2	O
)	O
pred	O
=	O
0.71	O
)	O
using	O
seven	O
compounds	O
as	O
a	O
test	O
set	O
for	O
external	O
validation	I:C1519941
.	O

We	O
also	O
confirmed	O
the	O
excellent	O
predictability	O
of	O
the	O
3D	O
-	O
QSAR	O
model	O
for	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activation	B:C1514758
(	O
r	O
(	O
2	O
)	O
pred	O
=	O
0.71	O
)	O
using	O
seven	O
compounds	O
as	O
a	O
test	O
set	O
for	O
external	O
validation	I:C1519941
.	O

We	O
also	O
confirmed	O
the	O
excellent	O
predictability	O
of	O
the	O
3D	O
-	O
QSAR	O
model	O
for	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activation	O
(	O
r	O
(	O
2	O
)	O
pred	O
=	O
0.71	O
)	O
using	O
seven	O
compounds	B:C1254351
as	O
a	O
test	O
set	O
for	O
external	O
validation	I:C1519941
.	O

We	O
also	O
confirmed	O
the	O
excellent	O
predictability	O
of	O
the	O
3D	O
-	O
QSAR	O
model	O
for	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activation	O
(	O
r	O
(	O
2	O
)	O
pred	O
=	O
0.71	O
)	O
using	O
seven	O
compounds	O
as	O
a	O
test	O
set	O
for	O
external	B:C1519941
validation	I:C1519941
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	B:C3161035
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	O
candidates	I:C1254351
with	O
minimized	O
DDI	O
risk	O
related	O
to	O
enzyme-	O
induction	I:C0014431
in	O
the	O
early	O
drug	O
-	I:C0920472
discovery	I:C0920472
stage	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	O
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
constitutive	B:C0914906
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	O
candidates	I:C1254351
with	O
minimized	O
DDI	O
risk	O
related	O
to	O
enzyme-	O
induction	I:C0014431
in	O
the	O
early	O
drug	O
-	I:C0920472
discovery	I:C0920472
stage	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	O
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	B:C1514758
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	O
candidates	I:C1254351
with	O
minimized	O
DDI	O
risk	O
related	O
to	O
enzyme-	O
induction	I:C0014431
in	O
the	O
early	O
drug	O
-	I:C0920472
discovery	I:C0920472
stage	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	O
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	B:C1254351
candidates	I:C1254351
with	O
minimized	O
DDI	O
risk	O
related	O
to	O
enzyme-	O
induction	I:C0014431
in	O
the	O
early	O
drug	O
-	I:C0920472
discovery	I:C0920472
stage	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	O
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	O
candidates	I:C1254351
with	O
minimized	O
DDI	B:C0687133
risk	O
related	O
to	O
enzyme-	O
induction	I:C0014431
in	O
the	O
early	O
drug	O
-	I:C0920472
discovery	I:C0920472
stage	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	O
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	O
candidates	I:C1254351
with	O
minimized	O
DDI	O
risk	O
related	O
to	O
enzyme-	B:C0014431
induction	I:C0014431
in	O
the	O
early	O
drug	O
-	I:C0920472
discovery	I:C0920472
stage	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	O
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
constitutive	O
androstane	I:C0914906
receptor	I:C0914906
activating	O
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	O
candidates	I:C1254351
with	O
minimized	O
DDI	O
risk	O
related	O
to	O
enzyme-	O
induction	I:C0014431
in	O
the	O
early	O
drug	B:C0920472
-	I:C0920472
discovery	I:C0920472
stage	O
.	O

